Akèy › Maladi Crohn › Lwizyàn
Etid klinik pou Maladi Crohn nan Lwizyàn
11 etid pou Maladi Crohn ap chèche patisipan nan sit nan Lwizyàn.
Vil nan Lwizyàn
Tèks ofisyèl etid la (Anglè)
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Gastro Group and Endocenter: Mandeville, la /ID# 284186, Mandeville
- Metropolitan Gastroenterology Associates - Metairie /ID# 283922, Metairie
- Willis-Knighton Medical Center /ID# 280572, Shreveport
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Baton Rouge General Medical Center - Bluebonnet Campus, Baton Rouge
- Combined Gastro LLC, Lafayette
- GI Alliance, Metairie
Ap rekriteFaz 4
Laj 18 a 80 · Tout sèks · Mizajou Sep 30, 2026 · NCT06581328A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Gastroenterology Clinic of Acadiana, Lafayette
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07499232A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- Gastroenterology Clinic of Acadiana, Lafayette
- Delta Research Partners, LLC, West Monroe
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07196722Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Care Access - New Iberia, New Iberia
- Louisiana Research Center, Shreveport
Ap rekriteFaz 3
Laj 18 a 70 · Tout sèks · Mizajou Sep 24, 2026 · NCT06937099An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- GI Alliance - Baton Rouge-Site Number: 8400129, Baton Rouge
- Tandem Intermediate, LLC - Houma-Site Number: 8400034, Houma
- Texas Digestive Disease Consultants, PLLC d/b/a GI Alliance - Mandeville-Site Number: 8400128, Mandeville
- ak 4 plis
Ap rekriteFaz 3
Laj 16 a 80 · Tout sèks · Mizajou Sep 23, 2026 · NCT07184931A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- GI Alliance - Baton Rouge-Site Number: 8400129, Baton Rouge
- Texas Digestive Disease Consultants, PLLC d/b/a GI Alliance - Mandeville-Site Number: 8400128, Mandeville
- GI Alliance - Metairie-Site Number: 8400124, Metairie
- ak 1 plis
Ap rekriteFaz 3
Laj 16 a 80 · Tout sèks · Mizajou Sep 23, 2026 · NCT07184944A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
- Tandem Clinical Research, Houma
Ap rekriteFaz 2
Laj 18 a 85 · Tout sèks · Mizajou Sep 22, 2026 · NCT06226883A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- GI Alliance, Metairie
- Tulane University, New Orleans
Ap rekriteFaz 4
Laj 18 a 70 · Tout sèks · Mizajou Sep 9, 2026 · NCT06045754A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- Gastroenterology Clinic of Acadiana, Lafayette
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT07577843A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Lafayette
- Mirador Therapeutics Selected Site, Marrero
- Mirador Therapeutics Selected Site, Shreveport
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Mar 12, 2026 · NCT07113522Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.